iCAD, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US44934S2068
USD
3.87
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

0

Shareholding (Mar 2025)

FII

2.25%

Held by 15 FIIs

DII

86.78%

Held by 12 DIIs

Promoter

0.00%

How big is iCAD, Inc.?

22-Jun-2025

As of Jun 18, iCAD, Inc. has a market capitalization of 104.27 million and reported net sales of 19.53 million with a net profit of -5.22 million for the latest four quarters. Shareholder's funds are 28.68 million, and total assets amount to 37.54 million.

As of Jun 18, iCAD, Inc. has a market capitalization of 104.27 million, classifying it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 19.53 million for the latest four quarters, while the net profit for the same period was -5.22 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 28.68 million and total assets amounting to 37.54 million.

Read More

What does iCAD, Inc. do?

22-Jun-2025

iCAD, Inc. specializes in advanced image analysis, workflow solutions, and radiation therapy for cancer detection and treatment, with a market cap of USD 104.27 million. As of March 2025, it reported net sales of USD 5 million and a net profit loss of USD 1 million.

Overview:<BR>iCAD, Inc. is a provider of advanced image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer, operating in the Pharmaceuticals & Biotechnology industry with a market cap of USD 104.27 Million.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 5 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -1 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 104.27 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.64 <BR>Return on Equity: -16.98% <BR>Price to Book: 3.39<BR><BR>Contact Details:<BR>Address: 98 Spit Brook Rd Ste 100, NASHUA NH: 03062-5737 <BR>Tel: ['1 603 8825200', '61 917 7491494'] <BR>Fax: 1 603 8803843 <BR>Website: http://www.icadmed.com

Read More

Should I buy, sell or hold iCAD, Inc.?

22-Jun-2025

Who are in the management team of iCAD, Inc.?

22-Jun-2025

As of March 2022, the management team of iCAD, Inc. includes Mr. Michael Klein as Executive Chairman and CEO, along with independent directors Mr. Nathaniel Dalton, Dr. Rakesh Patel, Mr. Andrew Sassine, and Dr. Susan Wood.

As of March 2022, the management team of iCAD, Inc. includes Mr. Michael Klein, who serves as the Executive Chairman of the Board and Chief Executive Officer. Additionally, the board consists of independent directors: Mr. Nathaniel Dalton, Dr. Rakesh Patel, Mr. Andrew Sassine, and Dr. Susan Wood.

Read More

Is iCAD, Inc. technically bullish or bearish?

20-Sep-2025

As of July 10, 2025, iCAD, Inc. shows a bullish technical trend with strong daily moving averages and Bollinger Bands, despite mixed signals from the MACD and Dow Theory, while significantly outperforming the S&P 500 year-to-date and over the past year.

As of 10 July 2025, the technical trend for iCAD, Inc. has changed from mildly bullish to bullish. The daily moving averages are bullish, and both the weekly and monthly Bollinger Bands indicate a bullish stance. However, the MACD shows a mildly bearish signal on the weekly timeframe, while the monthly MACD is bullish. The KST is bullish on both weekly and monthly timeframes, but Dow Theory indicates a bearish trend on the monthly level. <BR><BR>In terms of performance, iCAD has significantly outperformed the S&P 500 year-to-date with a return of 111.48% compared to 12.22%, and over the past year, it has returned 184.56% against the S&P 500's 17.14%. Overall, the current technical stance is bullish, albeit with some mixed signals in the indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor long term growth as Net Sales has grown by an annual rate of -8.90% and Operating profit at 6.29% over the last 5 years

 
2

Flat results in Mar 25

3

Risky - Negative EBITDA

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 103 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.64

stock-summary
Return on Equity

-16.98%

stock-summary
Price to Book

3.34

Revenue and Profits:
Net Sales:
5 Million
(Quarterly Results - Mar 2025)
Net Profit:
-1 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
20.19%
0%
20.19%
6 Months
96.95%
0%
96.95%
1 Year
184.56%
0%
184.56%
2 Years
7.8%
0%
7.8%
3 Years
-8.29%
0%
-8.29%
4 Years
-74.9%
0%
-74.9%
5 Years
-62.46%
0%
-62.46%

iCAD, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-8.90%
EBIT Growth (5y)
6.29%
EBIT to Interest (avg)
-9.09
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.64
Sales to Capital Employed (avg)
0.69
Tax Ratio
1.81%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
36.34%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.50
EV to EBIT
-14.79
EV to EBITDA
-16.72
EV to Capital Employed
8.01
EV to Sales
4.51
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-54.19%
ROE (Latest)
-16.98%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
Bearish
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 8 Schemes (10.96%)

Foreign Institutions

Held by 15 Foreign Institutions (2.25%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is -9.26% vs 28.57% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is 11.11% vs 50.00% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4.90",
          "val2": "5.40",
          "chgp": "-9.26%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.00",
          "val2": "-0.70",
          "chgp": "-42.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.80",
          "val2": "-0.90",
          "chgp": "11.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-231.60%",
          "val2": "-159.80%",
          "chgp": "-7.18%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 13.29% vs -12.63% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 20.00% vs 29.29% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "19.60",
          "val2": "17.30",
          "chgp": "13.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.50",
          "val2": "-7.30",
          "chgp": "24.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.60",
          "val2": "-7.00",
          "chgp": "20.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-310.30%",
          "val2": "-444.00%",
          "chgp": "13.37%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQstock-summary
Mar'25
Dec'24
Change(%)
Net Sales
4.90
5.40
-9.26%
Operating Profit (PBDIT) excl Other Income
-1.00
-0.70
-42.86%
Interest
0.30
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-0.80
-0.90
11.11%
Operating Profit Margin (Excl OI)
-231.60%
-159.80%
-7.18%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Mar 2025 is -9.26% vs 28.57% in Dec 2024

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Mar 2025 is 11.11% vs 50.00% in Dec 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
19.60
17.30
13.29%
Operating Profit (PBDIT) excl Other Income
-5.50
-7.30
24.66%
Interest
0.00
0.00
Exceptional Items
-0.20
0.00
Consolidate Net Profit
-5.60
-7.00
20.00%
Operating Profit Margin (Excl OI)
-310.30%
-444.00%
13.37%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 13.29% vs -12.63% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 20.00% vs 29.29% in Dec 2023

stock-summaryCompany CV
About iCAD, Inc. stock-summary
stock-summary
iCAD, Inc.
Pharmaceuticals & Biotechnology
iCAD, Inc. is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The Company provides image analysis and clinical decision support solutions for mammography, Magnetic Resonance Imaging and Computed Tomography imaging. It operates in two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy). The Detection segment consists of its advanced image analysis and workflow products, and the Therapy segment consists of its radiation therapy products. The Company sells its products through its direct sales organization, as well as through various original equipment manufacturer partners, distributors and resellers. It develops and markets computer-aided detection (CAD) solutions for digital and film-based mammography systems. Its Axxent SPX Controller includes an optimized skin treatment arm customized for compatibility in confined patient treatment rooms in physician office-based facilities.
Company Coordinates stock-summary
Company Details
98 Spit Brook Rd Ste 100 , NASHUA NH : 03062-5737
stock-summary
Tel: 1 603 882520061 917 7491494
stock-summary
Registrar Details